Discover insights into Anavex's ATTENTION-AD OLE trial results for early Alzheimer's, presented at AD/PD 2025. Click here to ...
Life Sciences announced that over three years of continuous treatment with blarcamesine, ANAVEX2-73, demonstrated significantly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback